Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fry

Showing results (111-120 of 201) with videos related to

Pageof 21
Sort By:
Cancer Research|March 1, 1985
Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitroL H Matherly, M K Voss, L A Anderson, et al.
Seminars in Oncology|July 26, 2002
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancerLee F Allen, Peter F Lenehan, Irene A Eiseman, et al.
Molecular Pharmacology|August 1, 1993
Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activityD W Fry, T J Boritzki, R C Jackson, et al.
Journal of Medicinal Chemistry|March 28, 1997
Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinasesJ Singh, E M Dobrusin, D W Fry, et al.
Clinical and Experimental Pharmacology & Physiology|May 1, 1996
Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitroW A Denny, G W Rewcastle, A J Bridges, et al.
Biochemical Pharmacology|November 1, 1988
Inhibition of type II topoisomerase by fostriecinT J Boritzki, T S Wolfard, J A Besserer, et al.
Anticancer Research|June 16, 1999
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitorsY Sun, D W Fry, P Vincent, et al.
Journal of Medicinal Chemistry|September 15, 1995
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, A J Bridges, D W Fry, et al.
Journal of Medicinal Chemistry|June 6, 1997
Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptorG W Rewcastle, A J Bridges, D W Fry, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|November 19, 2005
Translation squared: improving asthma care for high-disparity populations through a safety net practice-based research networkElvan C Daniels, Janice Bacon, Sandra Denisio, et al.
Pageof 21

Showing results (111-120 of 201) with videos related to

Sort By:
Pageof 21
Cancer Research|March 1, 1985
Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitroL H Matherly, M K Voss, L A Anderson, et al.
Seminars in Oncology|July 26, 2002
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancerLee F Allen, Peter F Lenehan, Irene A Eiseman, et al.
Molecular Pharmacology|August 1, 1993
Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activityD W Fry, T J Boritzki, R C Jackson, et al.
Journal of Medicinal Chemistry|March 28, 1997
Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinasesJ Singh, E M Dobrusin, D W Fry, et al.
Clinical and Experimental Pharmacology & Physiology|May 1, 1996
Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitroW A Denny, G W Rewcastle, A J Bridges, et al.
Biochemical Pharmacology|November 1, 1988
Inhibition of type II topoisomerase by fostriecinT J Boritzki, T S Wolfard, J A Besserer, et al.
Anticancer Research|June 16, 1999
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitorsY Sun, D W Fry, P Vincent, et al.
Journal of Medicinal Chemistry|September 15, 1995
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, A J Bridges, D W Fry, et al.
Journal of Medicinal Chemistry|June 6, 1997
Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptorG W Rewcastle, A J Bridges, D W Fry, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|November 19, 2005
Translation squared: improving asthma care for high-disparity populations through a safety net practice-based research networkElvan C Daniels, Janice Bacon, Sandra Denisio, et al.
Pageof 21